Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.

• 2024.11.05

  • News Release

  PDRadiopharma Inc. Receives “Controlled Medical Device” Certification for Brain Imaging Analysis Program “AMYclz® Neuro”

• 2024.10.23

  • News Release

  PeptiDream Announces Upcoming Presentation of CA9-Targeting PD-32766 Program at the Annual Meeting of the Japan Society of Urologic Oncology（PeptiDream Inc.）

• 2024.10.01

  • News Release

  PDRadiopharma, a PeptiDream Company, and Curium Announce Strategic Partnership for the Development and Commercialization of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T in Japan

• 2024.10.01

  • Information

  Announcement of New Management Structure

• 2024.09.30

  • News Release

  Launch of Medical DX (Digital Transformation) Solutions “Bridgea TIMER Guide” and “onti-d”

• 2024.09.03

  • News Release

  Approval of Partial Change to the Indication of AMYViD®,a PET Imaging Agent for Detecting Beta Amyloid

• 2024.07.01

  • News Release

  Dr. Masato Murakami Appointed as President and Representative Director of PDRadiopharma（PeptiDream Inc.）

• 2024.07.01

  Announcement of New Management Structure

• 2024.05.22

  • News Release

  Announcement of listing on the NHI Drug Price Standard of AMYViD®, a PET Imaging Agent for Detecting Beta Amyloid

• 2023.12.22

  • News Release

  Approval of Partial Change to the Indication of MyoMIBG® -I 123 Injection for Cardiac Scintigraphy for Patients with Parkinson’s Disease and Dementia with Lewy Bodies